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Background: Exposure to ionizing radiation (IR) is the best-established risk factor for thyroid 
cancer (TC) but genetic variation could also play a role. The DNA mismatch repair (MMR) 
pathway counteracts carcinogenesis through the supression of genetic instability and several 
lines of evidence suggest that altered function or expression of MMR proteins may also be 
implicated in TC pathogenesis. Objective: We aimed to evaluate the potential modifying role of 
a panel of eight MMR single nucleotide polymorphisms (SNPs) on the individual susceptibility 
to non-familial differentiated TC.  Design: A small-scale hospital-based case-control study was 
performed in a Caucasian Portuguese population, comprising 106 histologically confirmed 
differentiated TC patients and 212 age and gender matched controls. DNA mismatch repair 
SNPs rs1799977 (MLH1), rs26279 and rs184967 (MSH3), rs5745325 and rs5745549 (MSH4), 
rs5742933 (PMS1), rs175080 (MLH3) and rs1042821 (MSH6) were genotyped using the 
TaqMan allelic discrimination assay and the genotype-associated TC risk was estimated by 
multivariate logistic regression analysis. Results: The homozygous variant genotype of 
rs1042821 (MSH6) was significantly associated with increased differentiated TC risk, both 
under a codominant model (Glu/Glu vs. Gly/Gly: adjusted OR=3.42; 95%CI=1.04-11.24; 
p=0.04) and a recessive model (Glu/Glu vs. [Gly/Glu + Gly/Gly]: adjusted OR=3.84; 
95%CI=1.18-12.44; p=0.03). This association was also observed after histological and gender 
stratification, both in the follicular subset (adjusted OR=20.98; 95%CI=1.08-406.53; p=0.04 – 
codominant model; adjusted OR=23.70; 95%CI=1.25-449.32; p=0.04 – recessive model) and in 
the female subset (adjusted OR=4.78; 95%CI=1.17-19.56; p=0.03 – codominant model; 
adjusted OR=5.42; 95%CI=1.34-21.92; p=0.02 – recessive model). No significant associations 
were observed for the remaining SNPs. Conclusion: Our data supports the idea that the MSH6 
rs1042821 SNP may contribute to differentiated TC susceptibility, particularly of the follicular 
type. The risk increase is also apparent in women. Acknowledgement: This study was supported 
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